SDP Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes

January 22, 2021

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).

“The management of anemia in patients with MDS is challenging as this patient population tends to be older and often have non-hematological comorbidities which can make them relatively intolerant to therapy. Given the high unmet medical need, we are looking forward to learning more about the potential of TP-0184 in this patient population,” said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, SDP Oncology.

“SDP Oncology keeps breaking new ground,” said Kelvyn Cullimore, president and CEO of BioUtah. “With this latest study, the company is advancing a new potential treatment for the management of anemia patients with MDS.”

The Phase 1 part of the study will assess the safety and tolerability of oral TP-0184 and establish the dose for future studies. The Phase 2 portion of the study will determine the effect of TP-0184 on the treatment of anemia in terms of hemoglobin increase, reduction in red blood cell transfusions and being red blood cell transfusion-free for at least eight weeks.

Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT04623996).